Haematologica, Vol 92, Issue 3, e37-e40 doi:10.3324/haematol.10351
Copyright © 2007 by Ferrata Storti Foundation
S. Koida ,
K. Tsukasaki ,
T. Tsuchiya ,
H. Harasawa ,
T. Fukushima ,
Y. Yamada ,
K. Ohshima ,
S. Kamihira ,
M. Kikuchi ,
M. Tomonaga
Lymphoma of the thyroid is almost exclusively derived from B cells of mucosa-associated lymphoid tissue (MALT), and frequently co-exist with autoimmune thyroiditis in which most infiltrating cells are of Th1 cell origin. We present here two rare cases of peripheral T-cell lymphoma (PTCL) based on chronic thyroiditis with the phenotype CD3+, CD4+, CD8–, TCR
ß+. Furthermore, lymphoma cells in both cases were CXCR3+, CCR5+ and ST2(L)–, suggesting a Th1 cell origin. Eight of 11 cases of PTCL of the thyroid in the literature, including our cases, were associated with thyroiditis. Except for one tumor of 
T-cell type, all of the five lymphomas analyzed for CD4 expression were positive for the antigen. Among them, both those examined for chemokine receptors were phenotypically of Th1-cell origin with a background of thyroiditis, suggesting that Th1 activation induced by chronic inflammation could lead to PTCL of themselves as well as MALT-lymphoma of B cells.
Primary lymphoma of the thyroid accounts for only 2% to 4% of thyroid malignancies and less than 2% of extranodal lymphomas.1 Primary thyroid lymphoma is frequently associated with chronic thyroiditis in which most infiltrating cells are Th1 cells.2 In contrast, lymphoma cells of the thyroid are exclusively of B-cell phenotype.1,2 The majority are aggressive diffuse large B-cell lymphomas and the second most common histologic type is mucosa-associated lymphoid tissue (MALT)-B-lymphoma.1 There is evidence that large-cell lymphomas probably evolve from persistent low-grade MALT -B-lymphomas, suggesting a morphologic progression from chronic lymphocytic thyroiditis to low-grade MALT lymphoma and subsequently to high-grade large-cell lymphoma.1,3 In contrast, primary T-cell lymphoma of the thyroid is extremely rare, and little is known about the origin or phenotype of the T-cells. 4–12 We report here two rare cases of T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis.
Case 1
A 61-year-old man was referred to our hospital with a 16-month history of a progressively enlarging thyroid mass without symptoms. Physical examination revealed only diffuse thyroid enlargement. Laboratory data were as follows: leukocyte count 10300 (stab 10%, seg 41%, mono 1%, eosino 2%, lymphocytes 19%, abnormal lymphocytes 27%)/µL, RBC 4.83x106/µL, hemoglobin 15.0g/dl, platelets 26.5x104/µL, lactate dehydrogenase (LDH) 148 IU/l (normal range; 119–229) and soluble interleukin-2 receptor (sIL2R) 2048 U/mL (normal range; 145–518). Small to medium-sized abnormal lymphocytes with convoluted nucleoli, and relatively condensed chromatin were observed in peripheral blood (Figure 1A). Ultrastructual examination revealed that nuclei had some lobulation, but less than that of cerebriformed nuclei in typical Sezary cells (Figure 1B).1) A flow cytometric analysis of peripheral blood mononuclear cells (PBMNC) showed that the neoplastic cells were positive for mature helper T-cell markers (CD3, CD4, CD5, CD7, CD45RO and TCRß) but negative for B cell markers (CD19 and CD20), NK cell markers (CD16 and CD56) and activation markers (CD25 and DR). Bone marrow (BM) aspiration demonstrated no neoplastic cell infiltration. Serum-test results were negative for human T-lymphotropic virus type-1 (HTLV-1). Southern blotting revealed PBMNC to be positive for clonal rearrangement of the T-cell receptor Cß-chain gene, but negative for integration of the HTLV-1 provirus or Epstein Barr virus. Thyroid functions (fT3, fT4 and TSH) were within the normal range, but serum-test results were positive for anti-thyroglobulin antibody and anti-microsome antibody. A magnetic resonance image scan of revealed bilateral thyroid enlargement without lymphadenopathy. An open biopsy of the thyroid showed diffuse infiltration of small to medium-sized atypical lymphocytes in thyroid follicles associated with lymphoepithelial lesions (Figures 1C, 1D). Immunohistochemistry revealed that lymphoma cells were mature T-cells with the phenotype CD3+, CD4+, CD8–, CD20–, CD56– (Figures 1E, 1F). Furthermore, analysis of chemokine receptors revealed that lymphoma cells were CXCR3+, CCR5+ and ST-2–, suggesting a Th1 cell origin (Figures 1G, 1H, 1I).13 Results of flow cytometric analysis of a cell suspension from the thyroid were similar to those of PBMNC. Furthermore, the analysis revealed that leukemic cells were CCR7+ and CCR4–, supporting a Th1 cell origin. The patient was diagnosed as having peripheral T-cell lymphoma (PTCL) of the thyroid gland with leukemic manifestation, and started on CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. After 3 cycles of CVP, partial remission of the lymphoma was achieved and the therapy was discontinued because of peripheral numbness associated with vincristine. He is still alive with a residual thyroid mass and leukemic-manifestation confirmed by TCR-Southern blotting for more than four years.
Case 2
A 68-year-old man, who had been treated for Hashimoto’s thyroiditis and hypertension for 10 years, presented with a 3-week history of a progressively enlarging thyroid mass with dyspnea. Physical examination revealed diffuse thyroid enlargement with cervical lymphadenopathy. Laboratory data were as follows: WBC 5200/uL, Hb 13.0 g/dL, platelet 26.6X104/uL, LDH 398 IU/L, sIL2R 1534 U/mL and negative for HTLV-1 antibody. Abnormal lymphocytes were not detected in PB and BM. Computed tomography revealed bilateral thyroid enlargement with lymphadenopathy. An open biopsy of the thyroid showed diffuse infiltration of large atypical lymphocytes (Figures 2A, 2B). Immunostaining of thyroid tissue and cell suspension revealed that lymphoma cells were mature helper T-cells with the phenotype CD3+, CD4+, CD8–, CD20–, CD25–, CD56–, TCRß+, DR– (Figures 2C, 2D). Furthermore, an analysis of chemokine receptors revealed that lymphoma cells were CXCR3+, CCR5+ and ST-2–, suggesting a Th1 cell origin (Figures 2E, 2F, 2G).13 After 5 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), complete remission of the PTCL was acheived. However, the patient died of lymphoma relapsing at the meninx five months after onset.
Most extranodal lymphomas are of B-cell origin and frequently follow chronic inflammation.3 PTCL of the thyroid is extremely rare, with only 11 cases, including our two cases, reported in the literature (Table 1).4–12 Eight of them were associated with hypothyroidism or anti-thyroid antibody. Pathology and stage of the lymphoma, and disease course varied. Immunophenotyping revealed that in one case, the lymphoma was ofT-cell type.7 Phenotypical findings in the other cases were distinct especially for CD4. All of the five patients analyzed for CD4 expression were positive for the antigen, irrespective of cell size or clinical course. Interestingly, both of the cases with CD4+ small cell infiltration, including case 1 in this study, showed a lymphoepithelial lesion, resembling MALT-B lymphoma. Among five CD4+ thyroid T-cell lymphomas, two examined for chemokine receptors had an apparent Th1 phenotype with CXCR3+, CCR5+ and ST-2–.13 In one case with leukemic manifestation, the cells were CCR7+, CCR4–, further supporting the phenotype. These findings in rare PTCL of the thyroid raise the possibility of a distinct clinicopathlogical disease entity, that is, primary T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis.
The classification of peripheral T-cell lymphoma remains to be clarified.1 Particularly, the unspecified type is considered a heterogeneous category. Recently, using the expression pattern of chemokine receptors, Th1-associated CXCR3 and CCR5 and the Th2-associated marker ST2(L), the PTCL lymphoma, unspecified, could be classified as functional (Th1/Th2 phenotype; positive for at least one antigen) or non-functional (Th0 phenotype; all negative) with prognostic significance.13 All cases excluding one T-cell lymphoma in Table 1 could be classified as PTCL lymphoma, unspecified.1 Among them the disease course was diverse as mentioned above, and was apparently associated with the size of the lymphoma cells. Chronic inflammation at various extranodal sites could cause MALT lymphoma of B-cell type.3 However, T-cell lymphoma has been reportedly rare at each site. Further phenotypical studies on chemokine receptors are necessary for extranodal lymphomas not only at the thyroid but also at other sites to evaluate the possible disease entity of MALT Th1-lymphoma associated with chronic inflammation.
Authors contributions: Satoshi Koida: Designed research, collected data, analyzed data, and wrote the manuscript.
Copyright © 2007 by Ferrata Storti Foundation
Online Only Articles |
Primary T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis
Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, and Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Department of Pathology, School of Medicine, Kurume University, Kurume, Japan, Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan, Department of Pathology, School of Medicine, Fukuoka University, Fukuoka, Japan
Correspondence and reprint requests to: Kunihiro Tsukasaki, Department of Hematology, Molecular Medicine Unit Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences 1-12-4 Sakamoto, Nagasaki, Japan, Tel: +81(95) 849-7111 Fax: +81(95) 849-7113, Email: tsukasak{at}net.nagasaki-u.ac.jp
ABSTRACT
 TOP ABSTRACT IntroductionCase reportDiscussionReferences |
|---|
Lymphoma of the thyroid is almost exclusively derived from B cells of mucosa-associated lymphoid tissue (MALT), and frequently co-exist with autoimmune thyroiditis in which most infiltrating cells are of Th1 cell origin. We present here two rare cases of peripheral T-cell lymphoma (PTCL) based on chronic thyroiditis with the phenotype CD3+, CD4+, CD8–, TCR
ß+. Furthermore, lymphoma cells in both cases were CXCR3+, CCR5+ and ST2(L)–, suggesting a Th1 cell origin. Eight of 11 cases of PTCL of the thyroid in the literature, including our cases, were associated with thyroiditis. Except for one tumor of T-cell type, all of the five lymphomas analyzed for CD4 expression were positive for the antigen. Among them, both those examined for chemokine receptors were phenotypically of Th1-cell origin with a background of thyroiditis, suggesting that Th1 activation induced by chronic inflammation could lead to PTCL of themselves as well as MALT-lymphoma of B cells.
Key words: T-cell lymphoma, Th1 phenotype, chemokine receptors, autoimmune thyroiditis.
Introduction
|
TOPABSTRACTIntroductionCase reportDiscussionReferences |
|---|
Primary lymphoma of the thyroid accounts for only 2% to 4% of thyroid malignancies and less than 2% of extranodal lymphomas.1 Primary thyroid lymphoma is frequently associated with chronic thyroiditis in which most infiltrating cells are Th1 cells.2 In contrast, lymphoma cells of the thyroid are exclusively of B-cell phenotype.1,2 The majority are aggressive diffuse large B-cell lymphomas and the second most common histologic type is mucosa-associated lymphoid tissue (MALT)-B-lymphoma.1 There is evidence that large-cell lymphomas probably evolve from persistent low-grade MALT -B-lymphomas, suggesting a morphologic progression from chronic lymphocytic thyroiditis to low-grade MALT lymphoma and subsequently to high-grade large-cell lymphoma.1,3 In contrast, primary T-cell lymphoma of the thyroid is extremely rare, and little is known about the origin or phenotype of the T-cells. 4–12 We report here two rare cases of T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis.
Case report
|
TOPABSTRACTIntroductionCase reportDiscussionReferences |
|---|
Case 1
A 61-year-old man was referred to our hospital with a 16-month history of a progressively enlarging thyroid mass without symptoms. Physical examination revealed only diffuse thyroid enlargement. Laboratory data were as follows: leukocyte count 10300 (stab 10%, seg 41%, mono 1%, eosino 2%, lymphocytes 19%, abnormal lymphocytes 27%)/µL, RBC 4.83x106/µL, hemoglobin 15.0g/dl, platelets 26.5x104/µL, lactate dehydrogenase (LDH) 148 IU/l (normal range; 119–229) and soluble interleukin-2 receptor (sIL2R) 2048 U/mL (normal range; 145–518). Small to medium-sized abnormal lymphocytes with convoluted nucleoli, and relatively condensed chromatin were observed in peripheral blood (Figure 1A). Ultrastructual examination revealed that nuclei had some lobulation, but less than that of cerebriformed nuclei in typical Sezary cells (Figure 1B).1) A flow cytometric analysis of peripheral blood mononuclear cells (PBMNC) showed that the neoplastic cells were positive for mature helper T-cell markers (CD3, CD4, CD5, CD7, CD45RO and TCR
ß) but negative for B cell markers (CD19 and CD20), NK cell markers (CD16 and CD56) and activation markers (CD25 and DR). Bone marrow (BM) aspiration demonstrated no neoplastic cell infiltration. Serum-test results were negative for human T-lymphotropic virus type-1 (HTLV-1). Southern blotting revealed PBMNC to be positive for clonal rearrangement of the T-cell receptor Cß-chain gene, but negative for integration of the HTLV-1 provirus or Epstein Barr virus. Thyroid functions (fT3, fT4 and TSH) were within the normal range, but serum-test results were positive for anti-thyroglobulin antibody and anti-microsome antibody. A magnetic resonance image scan of revealed bilateral thyroid enlargement without lymphadenopathy. An open biopsy of the thyroid showed diffuse infiltration of small to medium-sized atypical lymphocytes in thyroid follicles associated with lymphoepithelial lesions (Figures 1C, 1D). Immunohistochemistry revealed that lymphoma cells were mature T-cells with the phenotype CD3+, CD4+, CD8–, CD20–, CD56– (Figures 1E, 1F). Furthermore, analysis of chemokine receptors revealed that lymphoma cells were CXCR3+, CCR5+ and ST-2–, suggesting a Th1 cell origin (Figures 1G, 1H, 1I).13 Results of flow cytometric analysis of a cell suspension from the thyroid were similar to those of PBMNC. Furthermore, the analysis revealed that leukemic cells were CCR7+ and CCR4–, supporting a Th1 cell origin. The patient was diagnosed as having peripheral T-cell lymphoma (PTCL) of the thyroid gland with leukemic manifestation, and started on CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. After 3 cycles of CVP, partial remission of the lymphoma was achieved and the therapy was discontinued because of peripheral numbness associated with vincristine. He is still alive with a residual thyroid mass and leukemic-manifestation confirmed by TCR-Southern blotting for more than four years.
 View larger version (57K): [in a new window] [Download PPT slide] |
Figure 1. Histological analysis of a thyroid-gland biopsy sample and cytological analysis of peripheral blood from patient 1 with primary T-cell lymphoma of the thyroid gland with leukemic manifestation. (A) Cytomorphology of the lymphoma cell in the peripheral blood (Wright-Giemsa, original magnification x1000). (B) Ultrastructural morphology of the lymphoma cell in the peripheral blood. (C) The tumor cells surround and partially infiltrate thyroid follicles (stained with hematoxylin and eosin; x40). (D) Small to medium-sized lymphoma cells showing marked nuclear irregularity and rare mitoses associated with lymphoepithelial lesions in thyroid follicles. The lymphoma cells strongly express CD4 (x400) (E), CXCR3 (x200) (F) and CCR5 (x400) (G), but not L26 (x200) (H) and ST1 (x400) (I).
|
A 68-year-old man, who had been treated for Hashimoto’s thyroiditis and hypertension for 10 years, presented with a 3-week history of a progressively enlarging thyroid mass with dyspnea. Physical examination revealed diffuse thyroid enlargement with cervical lymphadenopathy. Laboratory data were as follows: WBC 5200/uL, Hb 13.0 g/dL, platelet 26.6X104/uL, LDH 398 IU/L, sIL2R 1534 U/mL and negative for HTLV-1 antibody. Abnormal lymphocytes were not detected in PB and BM. Computed tomography revealed bilateral thyroid enlargement with lymphadenopathy. An open biopsy of the thyroid showed diffuse infiltration of large atypical lymphocytes (Figures 2A, 2B). Immunostaining of thyroid tissue and cell suspension revealed that lymphoma cells were mature helper T-cells with the phenotype CD3+, CD4+, CD8–, CD20–, CD25–, CD56–, TCR
ß+, DR– (Figures 2C, 2D). Furthermore, an analysis of chemokine receptors revealed that lymphoma cells were CXCR3+, CCR5+ and ST-2–, suggesting a Th1 cell origin (Figures 2E, 2F, 2G).13 After 5 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), complete remission of the PTCL was acheived. However, the patient died of lymphoma relapsing at the meninx five months after onset.
 View larger version (50K): [in a new window] [Download PPT slide] |
Figure 2. Histological analysis of a thyroid-gland biopsy sample and cytological analysis of peripheral blood from patient 2 with primary T-cell lymphoma of the thyroid gland. (A) The tumor cells infiltrate muscle without thyroid a structure (stained with hematoxylin and eosin; x40). (B) Large lymphoma cells showing some nuclear irregularity and occasional mitoses. The lymphoma cells strongly express CD4 (x400) (D), CXCR3 (x400) (E) and CCR5 (x400) (F), but not L26 (x400) (C) and ST1 (x400) (G).
|
Discussion
|
TOPABSTRACTIntroductionCase reportDiscussionReferences |
|---|
Most extranodal lymphomas are of B-cell origin and frequently follow chronic inflammation.3 PTCL of the thyroid is extremely rare, with only 11 cases, including our two cases, reported in the literature (Table 1).4–12 Eight of them were associated with hypothyroidism or anti-thyroid antibody. Pathology and stage of the lymphoma, and disease course varied. Immunophenotyping revealed that in one case, the lymphoma was of
T-cell type.7 Phenotypical findings in the other cases were distinct especially for CD4. All of the five patients analyzed for CD4 expression were positive for the antigen, irrespective of cell size or clinical course. Interestingly, both of the cases with CD4+ small cell infiltration, including case 1 in this study, showed a lymphoepithelial lesion, resembling MALT-B lymphoma. Among five CD4+ thyroid T-cell lymphomas, two examined for chemokine receptors had an apparent Th1 phenotype with CXCR3+, CCR5+ and ST-2–.13 In one case with leukemic manifestation, the cells were CCR7+, CCR4–, further supporting the phenotype. These findings in rare PTCL of the thyroid raise the possibility of a distinct clinicopathlogical disease entity, that is, primary T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis. |
View this table: [in a new window] [Download PPT slide] |
Table 1. Cases with primary T-cell lymphoma of the thyroid gland
|
T-cell lymphoma in Table 1 could be classified as PTCL lymphoma, unspecified.1 Among them the disease course was diverse as mentioned above, and was apparently associated with the size of the lymphoma cells. Chronic inflammation at various extranodal sites could cause MALT lymphoma of B-cell type.3 However, T-cell lymphoma has been reportedly rare at each site. Further phenotypical studies on chemokine receptors are necessary for extranodal lymphomas not only at the thyroid but also at other sites to evaluate the possible disease entity of MALT Th1-lymphoma associated with chronic inflammation. Autoimmune thyroiditis is associated with a dysfunction of suppressor T cells. This defect allows the over-growth of Th1 cells, which in turn activate the B cells in the thyroid to produce anti-thyroid antibodies.2 Recent studies have implicated different chemokines and their receptors in the pathogenesis, including migration pattern of lymphocytes, of different inflammatory diseases including autoimmune thyroid diseases (AITDs).2 Most infiltrating cells in AITDs are CD3+, CD4+ T cells with Th1-type chemokine receptors such as CXCR3 and CCR5.2,14 It is possible that chronic stimulation of the CD4 Th1 cells might lead to the development of malignant clones of themselves like MALT-B-lymphoma. This may explain the development of the PTCL with Th1 phenotype in our cases. However, in the present study, a functional analysis such as the measurement of cytokine levels in each case was difficult. Furthermore, the reason for the much higher frequency of MALT-B-lymphomas than PTCL as extranodal lymphomas following chronic inflamation remains unknown.
To our knowledge, the two cases in our study are the first report of primary T-cell lymphoma of the thyroid gland with chemokine receptors of Th1 phenotype complicating autoimmune thyroiditis.
Footnotes
Authors contributions: Satoshi Koida: Designed research, collected data, analyzed data, and wrote the manuscript.
Kunihiro Tsukasaki: Designed research, analyzed data, and edited the manuscript.
Takeshi Tsuchiya, Hitomi Harasawa, Takuya Fukushima, Yasuaki Yamada, Koichi Ohshima, Shimeru Kamihira and Masahiro
Kikuchi. : Provided guidance for diagnosis of PTCL of the thyroid.
Masao Tomonaga: Provided guidance for the study design, edited the manuscript
References
|
TOPABSTRACTIntroductionCase reportDiscussionReferences |
|---|
- Jaffe ES, Harris NL, Stein H, Vardiman JM. WHO classification of tumors - Pathology and genetica of tumors of haematopoietic and lymphoid tissues, Lyon: IARC Press. 2001.
- Rotondi M, Lazzeri E, Romagnani P, Serio M. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest, Feb 2003;26 2: 177-80.[Web of Science][Medline]
- Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer, Aug 2004;4 8: 644-53.[CrossRef][Web of Science][Medline]
- Mizukami Y, Matsubara F, Hashimoto T, Terahata S, Ikuta N, Nakamura S, Ooi A. Primary T-cell lymphoma of the thyroid. Acta Pathol Jpn, Dec 1987;37 12: 1987-95.[Medline]
- Suzuki Y, Sakane S, Sasaki M, Ueda S, Makino S, Matsuzuka F, et al. A case of primary thyroid T-cell lymphoma with infiltration of lymphoma cells in peripheral blood: diagnosed by DNA analysis. Nippon Naibunpi Gakkai Zasshi, Dec 20 1994;70 10: 1055-62.[Medline]
- Abdul-Rahman ZH, Gogas HJ, Tooze JA, Anderson B, Mansi J, Sacks NP, Finlayson CJ. T-cell lymphoma in Hashimoto’s thyroiditis. Histopathology 1996;29: 455-459.
- Yamaguchi M, Ohno T, Kita K. gamma/delta T-cell lymphoma of the thyroid gland. N Engl J Med, May 8 1997;336 19: 1391-2.
[Free Full Text] - Forconi F, Bocchia M, Marconcini S, Bigazzi C, Milani M, Fraternali-Orcioni G, Lauria F. CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland. Haematologica, Oct 1999;84 10: 946-8.
[Abstract/Free Full Text] - Coltrera MD. Primary T-cell lymphoma of the thyroid. Head Neck, Mar 1999;21 2: 160-3.[CrossRef][Web of Science][Medline]
- Freeman HJ. T cell lymphoma of the thyroid gland in celiac disease. Can J Gastroenterol, Jul–Aug 2000;14 7: 635-6.[Web of Science][Medline]
- Haciyanli M, Erkan N, Yorukoglu K, Sagol O, Harmancioglu O. Primary non-Hodgkin’s T-cell lymphoma of the thyroid gland complicating Hashimoto’s thyroiditis: case report. Thyroid, Aug 2000;10 8: 717-20.[CrossRef][Web of Science][Medline]
- Raftopoulos I, Vanuno D, Kouraklis G. Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 3. Primary T-cell lymphoma of the thyroid arising in a background of Hashimoto’s thyroiditis. J Clin Oncol, Aug 1 2001;19 15: 3576-80.
[Free Full Text] - Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, Hamasaki M, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood, Jan 1 2004;103 1: 236-41.[Medline]
- Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab, Oct 2001;86 10: 5008-16.
[Abstract/Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells Cancer Res., November 15, 2009; 69(22): 8611 - 8619. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||